This systematic review aimed to estimate the effects attributable to myo-inositol (MI) compared with inactive comparators across metabolic, endocrine, clinical, and reproductive outcomes in women with polyendocrine metabolic ovarian syndrome (PMOS), and to assess the certainty of evidence. Scopus, PubMed/MEDLINE, Web of Science, and the Cochrane Library were searched from inception to 31 July 2026. Studies evaluating MI, alone or with nonpharmacological components, were eligible. Risk of bias was assessed using RoB 2 and ROBINS-I, research integrity using RIGID/TRACT, and certainty of evidence using GRADE. Thirty-one studies were included (20 RCTs and 11 observational studies). Quantitative synthesis was restricted to low-integrity-risk RCTs comparing MI-containing interventions with inactive comparators. Participant totals varied across outcomes, with pooled analyses including between 70 and 376 participants. MI reduced LH levels (MD, −3.217 mIU/mL; 95% CI, −5.076 to −1.359; high certainty), likely reduced the LH/FSH ratio, and likely increased SHBG levels (moderate certainty). MI may also reduce free testosterone and irregular menses (low certainty). MI likely reduced HOMA-IR (MD, −0.972; 95% CI, −1.538 to −0.405; moderate certainty). When using assisted reproductive technology, MI likely increased clinical pregnancy (OR, 2.767; 95% CI, 1.151–6.651; moderate certainty). Across outcomes, certainty of evidence was frequently limited by small sample sizes, imprecision, and heterogeneity. Effects on several other outcomes remained insufficiently explored, and phenotype-stratified analyses were not feasible because studies did not report outcomes by PMOS phenotype. In conclusion, MI is associated with metabolic, endocrine, and reproductive benefits in PMOS, with certainty varying substantially across outcomes. Larger, phenotype-stratified RCTs with standardized dosing and adequate treatment duration are needed to confirm these findings.